Summary
RX 3117 can prove to be a breakthrough treatment option for pancreatic cancer and advanced bladder cancer patients.
RX 5902 is targeting the huge unmet demand in triple negative breast cancer indication.
There are certain risks that need to be considered before investing in Rexahn Pharmaceuticals.
Incorporated on January 14, 2005, Rexahn Pharmaceuticals (RNN) is a clinical-stage biopharmaceutical company focused on developing next-generation cancer therapies. The company currently boasts an attractive pipeline of novel therapeutics, of which RX-3117 and RX-5902 are in Phase 2 stage of the clinical development process. RX-3117 is being explored in the metastatic pancreatic cancer and advanced bladder cancer indications, while RX-5902 is being studied in the triple negative breast cancer indication.
Currently, there are many clinical-stage biopharmaceutical companies in the U.S. market. What makes Rexahn Pharmaceuticals special is the fact that it has chosen to take on some of the most difficult to treat and drug-resistant cancers with its mechanism of targeting and neutralizing specific proteins having a role in tumor growth. Hence, it follows, that any favorable news from these R&D programs can translate into huge upside potential for Rexahn Pharmaceuticals.
In this article, I will explain why I consider Rexahn Pharmaceuticals to be an attractive investment opportunity, especially for retail investors with above-average risk appetite.
